Close Menu

Meridian Bioscience

Industry executives said they believe ASRs are key components for laboratory directors who need to quickly develop critical diagnostic tests. 

A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.

The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.

The test is an improved version of one that was approved three years ago, and runs on the firm's illumigene molecular diagnostics platform.

The life science and diagnostics company's revenues were short of analyst expectations, though its earnings per share were in line with estimates.

The company's net earnings rose, and it reaffirmed its guidance of $195 million to $200 million in revenues for full year 2016.

The LAMP-based test is faster and more sensitive, allowing faster treatment and more accurate diagnosis for malaria patients.

There were more winners than losers in the 2015 GWDN Index, but some lost big.

The company's direct-from-blood test detects low levels of plasmodium parasitemia and runs on Meridian's Illumigene isothermal molecular diagnostic platform.

Pages

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.